Series A · Biotech · Berlin, Germany · Founded 2021 · 11–50 employees
Ariceum Therapeutics is a Berlin-based clinical-stage radiopharmaceutical biotech company developing next-generation targeted radiotherapeutics and diagnostics for aggressive and hard-to-treat cancers by advancing a pipeline of precision oncology candidates such as the novel radiolabeled peptide satoreotide and PARP-targeted compounds that combine imaging and therapeutic modalities; since its 2021 launch after acquiring key assets from Ipsen it has secured significant Series A financing and strategic partnerships to expand R&D, clinical programmes and global operations across Germany, Europe, North America and Australia.
No open roles listed right now.